



// 8 OCTOBER 2020

eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development

New hire will accelerate commercial development of Company's proprietary TriMix mRNA platform for oncology and infectious disease immunotherapies

Niel (Belgium)

eTheRNA immunotherapies NV ('eTheRNA' or 'The Company'), a clinical-stage company developing immunotherapies from its proprietary mRNA TriMix platform for the treatment of cancer and infectious diseases, today announced that Michael Mulqueen has been appointed VP of Business Development. Following 15 years at F. Hoffman-La Roche in both scientific and management roles, Michael continued his successful career in business development with innovative companies such as Synosia and Silence Therapeutics.

"I am delighted to join eTheRNA at this exciting stage of its development when the Company is making major progress with the core oncology mRNA immunotherapy pipeline and accelerating the development of its infectious disease vaccine platform," said Mulqueen. "I have maintained a strong interest in vaccines and RNA, having originally been a virology team leader at Roche and more recently head of BD at Silence Therapeutics."

CEO Steven Powell commented: "Michael will be a valuable addition to the team as we seek to leverage the potential of our TriMix platform both through our own pipeline development and through collaborations and partnerships."

About eTheRNA Immunotherapies NV

eTheRNA immunotherapies NV is developing immunotherapy and vaccine products for the treatment of cancer and infectious disease from its multiple RNA, formulation and manufacturing technology platforms. The company is headquartered in Belgium and was established in 2013 and its founding shareholders include Progress Pharma and VUB. eTheRNA is supported by an international group of specialised investors; BNP Fortis Private Equity, Boehringer Ingelheim Venture Funds, Everjoy Fortune PTE. LTD, Grand Decade Development Limited, Fund+, LSP, Novalis Lifesciences, Omega Funds, PMV and Ying Zhou Enterprise Management Company Limited who share the Company's ambition to build a world-leading company in the RNA field. To date, the Company has raised €63 million of venture funding. Further details relating to eTheRNA's R&D pipeline can be found at <https://www.etherna.be/immunotherapies-rd-pipeline/>.